Arimidex® Not Associated with Cognitive Impairment Among Postmenopausal Women at High Risk for Breast Cancer
October 10, 2008 — Researchers from the United Kingdom have reported that the use of the aromatase inhibitor Arimidex® (anastrozole) does not appear to be associated with cognitive impairment among postmenopausal women at a high risk of developing breast cancer. These results were recently published in the October, 2008 issue of Lancet Oncology.
United States Preventive Task Force Provides Recommendations for Colorectal Cancer Screening
October 10, 2008 — The United States Preventive Services Task Force (USPSTF) has recently issued recommendations for the screening of colorectal cancer. These recommendations were published in the Archives of Internal Medicine.
Nexavar® May Overcome Resistance to Arimidex® in Breast Cancer
October 10, 2008 — Researchers from Georgetown University have reported that the addition of Nexavar® (sorafenib) to Arimidex® (anastrozole) helps restore sensitivity to Arimidex among women with breast cancer. These results were recently presented at the 2008 annual American Society of Clinical Oncology (ASCO) breast cancer symposium.
Select news items provided by Reuters Health